Common Male Health Conditions: Heart Disease, Baldness, Gynecomastia, Hernias, and Testicular Cancer

Introduction

Men face specific health challenges that differ in prevalence, presentation, and outcomes compared to women. This guide covers common male health concerns including cardiovascular disease (the leading cause of death in men), androgenetic alopecia, gynecomastia, inguinal and other hernias, and testicular cancer. Understanding these conditions and their risk factors promotes early detection and improved outcomes.

Cardiovascular Disease in Men

Epidemiology

Statistic	Value
Leading cause of death in men	Yes (25% of all male deaths)
Lifetime risk after age 40	1 in 2 men
Average age of first heart attack	65
Men vs women: earlier presentation	Yes (men 7-10 years earlier)
Men vs women: mortality difference	Men have higher age-adjusted CVD mortality

Risk Factors

Risk Factor	Prevalence in Men	Impact
Hypertension (>130/80)	50% of men >45	2x risk of heart disease; 3x risk of stroke
Hyperlipidemia (LDL >130)	35% of men	1.5-2x risk
Diabetes	12% of men (20% >60)	2-4x risk
Smoking	14% of men	2-4x risk
Obesity (BMI >30)	35% of men	1.5-2x risk
Physical inactivity	30% of men	1.5x risk
Family history (early CVD)	Varies	1.5-2x risk
Low testosterone	15-20% of men >50	Emerging risk factor

Heart Attack Symptoms (May Differ from Women)

Typical (Common)	Atypical (More Common in Men vs Women)
Chest pain/pressure (80%)	Indigestion/heartburn
Radiation to left arm, jaw, back	Fatigue (less common in men)
Shortness of breath	Anxiety (less common)
Diaphoresis (sweating)
Nausea/vomiting

Prevention

Strategy	Recommendation	Evidence
Screen for hypertension	q1-2 years (normal) or q1 year (>120/80)	Strong
Lipid panel	q4-6 years starting age 20; earlier if risk factors	Strong
ASCVD risk calculator (Pooled Cohort Equations)	Age 40-75: calculate 10-year risk	Strong for statin decisions
Aspirin for primary prevention	Age 40-59 with 10-year risk >10% and no bleeding risk	Moderate (USPSTF 2022: C recommendation)
Statin for primary prevention	Age 40-75 with >7.5-10% 10-year risk and >1 risk factor	Strong
Mediterranean diet	Reduced CV events by 30% (PREDIMED trial)	Strong
Exercise (150 min/week moderate)	Reduced CV mortality by 25%	Strong
Smoking cessation	Risk declines to near-non-smoker after 15 years	Strong

Male Pattern Baldness (Androgenetic Alopecia)

Classification (Norwood-Hamilton Scale)

Stage	Description
I	Minimal recession (normal hairline)
II	Bilateral temporal recession (mature hairline)
III	Significant temporal recession (vertex may be involved)
III-vertex	Vertex loss with minimal temporal recession
IV	Temporal recession and vertex loss (bridge of hair remains)
V	Bridge of hair narrows
VI	Bridge of hair gone; extensive crown and vertex loss
VII	Only horseshoe-shaped fringe remaining (sides and back)

Pathophysiology

Factor	Role
Genetics	Androgen receptor (AR) gene on X chromosome; multiple other genes (HDAC9, AR, EDA2R, WNT10A)
Dihydrotestosterone (DHT)	DHT binds to androgen receptors on dermal papilla cells, miniaturizing hair follicles
Conversion	5-alpha-reductase (type II) converts testosterone to DHT in hair follicles
Pattern	Frontal and vertex scalp follicles are sensitive to DHT; occipital follicles are usually resistant
Inheritance pattern	Multifactorial (maternal and paternal lineage both contribute)

Treatment

Treatment	Efficacy	Mechanism	Side Effects	Notes
Minoxidil (Rogaine) 2% or 5%	Moderate (40-60% regrowth or slowed loss)	Vasodilator; prolongs anagen phase; unknown precise mechanism	Scalp irritation (5-10%); hypertrichosis (unwanted facial hair with 5%)	OTC; applies BID (2%) or once daily (5% foam); takes 4-12 months to see effect
Finasteride (Propecia) 1 mg	Moderate-high (60-80% maintain or improve)	5-alpha-reductase type II inhibitor; reduces DHT by 60-70%	Decreased libido (2-5%), ED (1-3%), decreased ejaculate volume, rare persistent sexual side effects	Prescription; tablet daily; takes 6-12 months; continued use needed
Dutasteride (Avodart) 0.5 mg	Similar to finasteride (may be slightly more effective)	Inhibits both type I and II 5-alpha-reductase; reduces DHT by 90%+	Similar to finasteride	Off-label for hair loss; more potent DHT suppression
Low-level laser therapy (LLLT)	Mild-moderate	Increases ATP, blood flow to follicles	Minimal	Expensive; limited evidence
Platelet-rich plasma (PRP)	Moderate (emerging)	Growth factors from platelets injected into scalp	Pain, swelling at injection	Variable protocol; multiple sessions needed
Hair transplant (FUT or FUE)	Excellent (definitive)	Transfer DHT-resistant follicles (occipital) to bald areas	Surgical risks, cost, scarring	Best candidates: stable hair loss; adequate donor supply

Gynecomastia

Definition and Prevalence

Aspect	Detail
Definition	Benign proliferation of male breast glandular tissue (>0.5 cm diameter, firm, subareolar)
Prevalence	30-60% of adolescent boys (peak 14-15); 50-70% of older men (peak 50-70)
Distinguish from pseudogynecomastia	Pseudogynecomastia: adipose tissue only (soft, no discrete mass) vs gynecomastia: firm glandular tissue

Causes

Category	Cause	Mechanism
Physiologic (most common)	Neonatal (maternal estrogens), puberty (transient T/E2 imbalance), aging (increased aromatase activity)	Imbalance between testosterone and estrogen
Pharmacologic (10-20%)	Spironolactone, H2 blockers (cimetidine), antiandrogens (bicalutamide, flutamide), finasteride, GnRH agonists, anabolic steroids, alcohol, marijuana, opioids, calcium channel blockers, amiodarone, highly active antiretroviral (HAART), tricyclics	Many mechanisms: antiandrogen, estrogen-like, increased prolactin
Pathologic	Hypogonadism (primary), hyperprolactinemia, hyperthyroidism, liver disease (cirrhosis), kidney disease (dialysis), testicular tumors (Leydig, Sertoli, hCG-producing), adrenal tumors, obesity (aromatization in fat)	Increased estrogen, decreased testosterone, increased prolactin

Evaluation

Test	Indication
History	Onset, progression, medications, drugs, symptoms of hypogonadism, testicular pain/mass
Physical	Palpate breast (glandular vs fatty, size, tenderness); testicular exam; thyroid, liver, and genital exam
Testosterone, LH, FSH	Hypogonadism evaluation
hCG, estradiol	If suspicious for hCG-secreting tumor
Prolactin	Hyperprolactinemia (pituitary cause)
TSH	Hyperthyroidism
LFTs, creatinine	Liver, kidney disease
Testicular ultrasound	If testicular mass/abnormality on exam
Mammography	If asymmetric, hard, fixed, or suspicious for male breast cancer
Breast biopsy	If suspicious features (unilateral, eccentric, hard, fixed, skin changes, bloody discharge)

Treatment

Severity	Treatment
Mild (<2 cm, recent onset)	Reassurance; address underlying cause; remove offending medication; treat underlying condition
Moderate (>3 cm, tender, persistent >6-12 months)	Medical therapy (if within 6-12 months of onset): tamoxifen 20 mg daily or raloxifene 60 mg daily; consider surgery if fails
Severe or chronic (>12 months, fibrotic)	Surgical reduction (subcutaneous mastectomy + liposuction); irreversible if present >12 months (fibrosis)
Underlying causes	Treat hypogonadism (TRT if indicated), hyperthyroidism, tumor; stop offending drug

Male Breast Cancer (Rare, <1% of all breast cancers)

Feature	Detail
Incidence	1 in 1,000 men lifetime
Mean age	67
Presentation	Painless, hard, unilateral, eccentric, fixed mass; may have nipple retraction, discharge, skin changes
Risk factors	BRCA2 mutation (100x risk), Klinefelter syndrome (50x risk), prior chest radiation, obesity, liver disease
Treatment	Modified radical mastectomy +/ radiation +/ endocrine therapy (tamoxifen if ER+) +/ chemotherapy

Hernias

Types

Type	Location	Contents	Prevalence in Men
Indirect inguinal hernia	Through internal inguinal ring into inguinal canal (may extend into scrotum)	Omentum, small bowel	90% of inguinal hernias in men
Direct inguinal hernia	Through Hesselbach triangle (medial to inferior epigastric vessels)	Usually omentum, rarely bowel	10% of inguinal hernias; more common in older men
Femoral hernia	Through femoral canal (below inguinal ligament)	Usually omentum/bowel	Less common in men (ratio 1:10 compared to women)
Umbilical hernia	Through umbilical ring	Omentum, fat	More common in obese men
Incisional hernia	Through prior surgical incision	Variable	10-20% after abdominal surgery
Hiatal hernia	Stomach protrudes through esophageal hiatus	Stomach	Common (increases with age)

Inguinal Hernia

Aspect	Detail
Lifetime risk in men	27%
Risk factors	Increased intra-abdominal pressure (heavy lifting, chronic cough, constipation, obesity, BPH/straining), smoking (impaired connective tissue), family history
Presentation	Bulge or lump in groin (may or may not be reducible); dull ache or heavy sensation; may radiate to testicle; worse with standing, straining
Diagnosis	Clinical exam (palpate inguinal canal while patient performs Valsalva); ultrasound if uncertain

Complications

Complication	Details	Urgency
Incarceration	Hernia contents cannot be reduced; may cause pain, nausea	Urgent (within days)
Strangulation	Blood supply to incarcerated contents is compromised; causes severe pain, vomiting, peritonitis	SURGICAL EMERGENCY (within hours)
Bowel obstruction	If bowel involved in incarcerated/strangulated hernia	EMERGENCY

Repair Options

Approach	Mesh	Advantages	Disadvantages	Recovery
Open (Lichtenstein tension-free)	Yes (polypropylene mesh)	Gold standard; local anesthesia possible; low recurrence (1-3%)	More postoperative pain; longer recovery vs laparoscopic	2-4 weeks light duty; 4-6 weeks full
Laparoscopic (TEP - total extraperitoneal)	Yes	Faster recovery; less pain; can repair bilateral	General anesthesia required; higher cost; steep learning curve	1-2 weeks light duty; 2-4 weeks full
Laparoscopic (TAPP - transabdominal preperitoneal)	Yes	Can explore contralateral side; good visualization	General anesthesia; enters peritoneum; higher risk of visceral injury	Same as TEP
Robotic (TAPP)	Yes	Enhanced dexterity, 3D visualization	Expensive; longer OR time	Same as laparoscopic
Watchful waiting	No (observation)	Avoids surgery/risks	Risk of incarceration/strangulation; symptoms may worsen	For asymptomatic or minimally symptomatic hernias in men with comorbidities

Testicular Cancer

Epidemiology and Risk Factors

Statistic	Value
Most common cancer in men 15-35	Yes
Lifetime risk	1 in 250
Incidence (US)	6 per 100,000 (increasing)
Median age at diagnosis	33
Cure rate	>95% (all stages combined)
Risk factors	Cryptorchidism (2-8x), family history (4-10x), personal history (25x for contralateral), Klinefelter syndrome, testicular atrophy, infertility, prior testicular cancer
Protective factors	None clearly established

Histologic Types

Type	Percentage of Germ Cell Tumors	Age Peak	Markers
Seminoma	45-55%	30-45	hCG (10-20%), normal AFP
Non-seminoma (all others)	45-55%	20-35
- Embryonal carcinoma	15-25%		hCG +/ AFP +/ LDH
- Yolk sac tumor	5-10%	<3 years (children); rare component in adults	AFP elevated
- Choriocarcinoma	1-5%		hCG very high
- Teratoma	3-10%		Variable; may have mature or immature elements
- Mixed (most common NSGCT)	40-50%		Variable

Staging (AJCC)

Stage	Description	AAFP	hCG	LDH
0	Intratubular germ cell neoplasia (carcinoma in situ)	Normal	Normal	Normal
I	Confined to testis (no nodal or distant mets)	May be elevated	May be elevated	May be elevated
IS	Persistent marker elevation after orchiectomy	Elevated	Elevated	Elevated
II	Retroperitoneal lymph node involvement	Variable	Variable	Variable
III	Distant metastases (lung, liver, brain, bone)	Variable	Variable	Elevated

Diagnosis

Test	Purpose
Testicular ultrasound (scrotal)	Distinguish intratesticular (cancer) from extratesticular (benign) mass
Serum tumor markers: AFP, hCG, LDH	Baseline; monitor treatment response
CT chest/abdomen/pelvis	Staging (metastasis evaluation)
Radical inguinal orchiectomy	Definitive diagnosis and treatment (NOT trans-scrotal biopsy)

Treatment by Stage

Stage	Seminoma	Non-seminoma
IA	Orchiectomy + surveillance or single-dose carboplatin (option) or radiation (less common)	Orchiectomy + surveillance (preferred) or RPLND or chemotherapy
IB	Orchiectomy + surveillance or carboplatin or radiation	Orchiectomy + RPLND or chemo (BEP x1-2) or surveillance
IS	Orchiectomy + chemo (BEP x3 or EP x4)	Orchiectomy + chemo (BEP x3 or EP x4)
IIA/IIB	Radiation or chemo (BEP x3 or EP x4)	Chemo (BEP x3 or EP x4) + RPLND if residual
IIC/III	Chemo (BEP x3 or EP x4) + RPLND if residual	Chemo (BEP x3 or EP x4) + RPLND if residual

Chemotherapy Regimens

Regimen	Drugs	Uses
BEP	Bleomycin, etoposide, cisplatin	Standard first-line (3 cycles for good risk; 4 for intermediate/poor)
EP	Etoposide, cisplatin	Alternative to BEP (if bleomycin contraindicated)
TIP	Paclitaxel, ifosfamide, cisplatin	Second-line (salvage)
VeIP	Vinblastine, ifosfamide, cisplatin	Second-line
High-dose chemo + stem cell rescue	Carboplatin + etoposide +/- ifosfamide	Third-line (salvage)

Post-Treatment Follow-up

Interval	Assessments
Year 1-2	q2-3 months: physical exam, tumor markers, CT chest/abdomen (if indicated)
Year 3	q3-4 months
Year 4-5	q6 months
Year 5+	Annually
Long-term	Monitor for late effects: secondary malignancy, CV disease, neuropathy, nephrotoxicity, hypogonadism, infertility

Sperm Banking

Recommendation	All men with testicular cancer should be offered sperm banking before treatment (orchiectomy rarely affects sperm count; chemo/radiation may cause permanent infertility)